1
Clinical Trials associated with Allogeneic bone marrow-derived mesenchymal stem cell therapy(Ottawa Hospital Research Institute)Cellular Immunotherapy for Septic Shock (CISS2) A Phase II Randomized Controlled Trial
Septic shock is associated with substantial burden in terms of both mortality and morbidity for survivors of this illness. Pre-clinical sepsis studies suggest that mesenchymal stem (stromal) cells may modulate inflammation, enhance pathogen clearance and tissue repair and reduce death. Our team has completed a Phase I dose escalation and safety clinical trial that evaluated mesenchymal stem cells (MSCs) in patients with septic shock. The Cellular Immunotherapy for Septic Shock (CISS) trial established that MSCs appear safe and that a randomized controlled trial (RCT) is feasible. Based on these data, the investigators have planned a phase II RCT (CISS2) at several Canadian academic centres which will evaluate safety, signals for clinical efficacy, and continue to examine potential mechanisms of action and biological effects of MSCs in septic shock.
100 Clinical Results associated with Allogeneic bone marrow-derived mesenchymal stem cell therapy(Ottawa Hospital Research Institute)
100 Translational Medicine associated with Allogeneic bone marrow-derived mesenchymal stem cell therapy(Ottawa Hospital Research Institute)
100 Patents (Medical) associated with Allogeneic bone marrow-derived mesenchymal stem cell therapy(Ottawa Hospital Research Institute)
100 Deals associated with Allogeneic bone marrow-derived mesenchymal stem cell therapy(Ottawa Hospital Research Institute)